CJ-30039

CJ-30039 is a small molecule drug developed as an incrementally modified version of fenofibric acid. It has been investigated primarily for the treatment of lipid metabolism disorders, with its main therapeutic area being endocrinology and metabolic diseases. The drug has undergone Phase 1 clinical trials to assess its safety and pharmacokinetic properties in healthy volunteers, including direct comparison with Lipidil Supra (fenofibrate). There is no evidence of regulatory approval or advanced clinical development beyond Phase 1. The mechanism of action is presumed to be similar to that of fenofibric acid, which acts as a peroxisome proliferator-activated receptor alpha (PPARα) agonist; however, explicit confirmation for CJ-30039's mechanism was not found in the available sources[1][2][9].